Emission characteristics of a prime mover for hybrid vehicle use by 375317 Allsup, Jerry R., Fleming, R. D.

Efficiency and emissions of a stratified charge engine optimized for various fuels/ by 312177 Evers, L. W., Fleming, R. D., Hurn, R. W., Society of Automotive Engineers (United States)

FGF-2 promotes osteocyte differentiation through increased E11/podoplanin expression by Ikpegbu, E, Basta, L, Clements, D, Fleming, R, Vincent, T, Buttle, D, Pitsillides, A, Staines, K, Farquharson, C

FGF-2 promotes osteocyte differentiation through increased E11/podoplanin expression by Ikpegbu, E, Basta, L, Clements, D, Fleming, R, Vincent, T, Buttle, D, Pitsillides, A, Staines, K, Farquharson, C

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. by Midgley, R, Kerr, D, Flaherty, K, Stevenson, J, Pratap, SE, Koch, K, Smith, D, Versola, M, Fleming, R, Ward, C, O'Dwyer, P, Middleton, MR

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098 by Brown, N, Williams, M, Arkenau, H, Fleming, R, Tolson, J, Yan, L, Zhang, J, Swartz, L, Singh, R, Auger, K, Lenox, L, Cox, D, Lewis, Y, Plisson, C, Searle, G, Saleem, A, Blagden, S, Mulholland, P

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors by Soria, J, Gan, H, Blagden, S, Plummer, R, Arkenau, H, Ranson, M, Evans, T, Zalcman, G, Bahleda, R, Hollebecque, A, Lemech, C, Dean, E, Brown, J, Gibson, D, Peddareddigari, V, Murray, S, Nebot, N, Mazumdar, J, Swartz, L, Auger, K, Fleming, R, Singh, R, Millward, M